Reaction

Tongue Ulceration reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,344 reports · 80 co-occurring drugs

As of the last recalculation, Tongue Ulceration appears in 3,344 FAERS reports alongside 80 co-occurring drug terms. The strongest observed disproportionality signal is ASENAPINE MALEATE (PRR 22.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Asenapine Maleate	31	22.5	22.5
Cabozantinib	131	17.6	17.7
Nystatin Ointment	68	16.5	16.5
Nystatin Cream	68	16.4	16.5
Nystatin	68	15.8	15.8
Buprenorphine Hydrochloride, Naloxone Hydrochloride	49	12.8	12.8
Regorafenib	22	11.9	11.9
Sorafenib	39	11.8	11.8
Chlorhexidine Gluconate	14	9.6	9.6
Aprepitant	25	8.5	8.5
Diphenhydramine Hydrochloride Capsule, Liquid Filled	27	7.9	7.9
Everolimus	61	7.6	7.6
Terbinafine Hydrochloride	10	7.0	7.0
Cyclobenzaprine Hydrochloride	10	6.9	7.0
Temozolomide	23	6.8	6.8
Posaconazole Delayed-Release	12	6.8	6.8
Peginterferon Alfa-2A	58	6.8	6.8
Extended Phenytoin Sodium	18	6.7	6.7
Hydroxyurea	22	6.5	6.5
Sulfasalazine	78	6.3	6.3
Hydrocortisone Sodium Succinate	9	6.0	6.0
Nicotine Polacrilex	36	5.9	5.9
Posaconazole	14	5.4	5.4
Adalimumab-Fkjp	39	5.3	5.3
Sunitinib Malate	33	5.3	5.3
Desloratadine	9	5.2	5.2
Adalimumab-Aaty	39	5.2	5.2
Miconazole Nitrate	7	5.0	5.0
Pertuzumab	21	4.8	4.8
Ribavirin	49	4.8	4.8
Adalimumab-Adaz	39	4.6	4.6
Tocilizumab	83	4.6	4.6
Fosaprepitant Dimeglumine	10	4.5	4.5
Cyclosporine	79	4.5	4.5
Exemestane	15	4.4	4.4
Ribociclib	21	4.2	4.2
Prochlorperazine Maleate	6	4.1	4.1
Lapatinib	10	4.0	4.0
Valacyclovir Hydrochloride	45	4.0	4.0
Niraparib	14	3.9	3.9
Tolvaptan	9	3.9	3.9
Oxybutynin	18	3.8	3.8
Fexofenadine	10	3.8	3.8
Pazopanib Hydrochloride	16	3.7	3.7
Budesonide, Glycopyrrolate, And Formoterol Fumarate	6	3.6	3.6
Alpelisib	5	3.6	3.6
Secukinumab	90	3.5	3.5
Rucaparib	5	3.5	3.5
Golimumab	44	3.2	3.2
Nicotine	20	3.1	3.1
Umeclidinium Bromide And Vilanterol Trifenatate	8	3.0	3.0
Lisdexamfetamine Dimesylate	15	2.8	2.8
Sarilumab	12	2.8	2.8
Panitumumab	7	2.8	2.8
Abatacept	61	2.8	2.8
Fluticasone Propionate And Salmeterol	18	2.7	2.7
Bevacizumab	53	2.7	2.7
Pemetrexed	9	2.6	2.6
Axitinib	8	2.6	2.6
Axicabtagene Ciloleucel	4	2.5	2.5
Palbociclib	38	2.5	2.5
Lenvatinib	13	2.5	2.5
Ibrutinib	31	2.4	2.4
Upadacitinib	31	2.4	2.4
Inclisiran	3	2.3	2.3
Romosozumab-Aqqg	5	2.3	2.3
Ruxolitinib	26	2.3	2.3
Venetoclax	22	2.2	2.2
Nivolumab	34	2.2	2.2
Naltrexone Hydrochloride And Bupropion Hydrochloride	3	2.2	2.2
Cetuximab	11	2.2	2.2
Siponimod	3	2.1	2.1
Pegfilgrastim	33	2.1	2.1
Avapritinib	4	2.1	2.1
Ixekizumab	12	2.0	2.0
Bimekizumab	6	1.8	1.8
Osimertinib	9	1.7	1.7
Valbenazine	7	1.7	1.7
Orlistat	6	1.4	1.4
Buprenorphine	21	1.4	1.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.